Lario Therapeutics awarded $2.4m to advance calcium channel platform

Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD

Lario Therapeutics has secured $2.4 million in new grant funding from The Michael J Fox Foundation for Parkinson’s Research and Wellcome to accelerate the development of its neuronal calcium channel drug discovery platform. The Edinburgh‑based biopharmaceutical company focuses on first‑in‑class precision medicines for epileptic and neurological disorders.

The awards will enable Lario to broaden its work on selective small‑molecule inhibitors of voltage‑gated neuronal calcium channels. As part of this…